Cansera provides products and services using digital biomarkers and tools.
We support patients being screened, evaluated or treated for cancer.
Our goal is to build tools that improve the outcomes for patients using scientific principles and evidence-based approaches. Cansera holds the exclusive worldwide commercial rights to both the quantified human performance status technologies and all the PiNK Test™ related intellectual property rights for the use of artificial intelligence for simultaneous use of clinical and molecular readouts.
PiNK Test
™
Towards realizing PiNK Test, Cansera has established unique partnerships with the Convergent Science Institute in Cancer (CSI-Cancer) laboratory at the University of Southern California (USC) that has developed the blood-based liquid biopsy test for early breast cancer detection (see https://early.usc.edu). Blood-based cancer screening is ideally suited for widespread distribution to the community, but neither the companies who promote these tools nor health systems have the information technology infrastructure for communicating results and tracking people who were screened this way. The product vision for the PiNK Test is a complementary approach together with current standard of care for women at average risk for breast cancer and those where the current standard of care has reduced accuracy such as women with dense breasts. We are working with CSI-Cancer to facilitate community-based cancer screening using a blood test.
For inquiries, please contact us at:
Copyright 2024